Please assess the completion status of the following clinical trial:

Trial Title: Hydroxychloroquine for COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Age above 18 years~* Women of childbearing age only: Must agree to practice continuous effective contraception for the duration of the study (a method which results in a failure rate less than 1% per year)~* Disease severe enough to require hospitalization~* QTc interval lower than 450 msec~Exclusion Criteria:~* Respiratory rate \>24/min~* Pregnancy (tested with a pregnancy test) or lactation~* Weight \<50 kg~* Hemodynamic/rhythm instability~* Acute myocardial infarction Type 1~* Use of concomitant medications that prolong the QT/QTc interval.~* Any regular concomitant medication which is contraindicated in the use together with HCQ~* Hypersensitivity to Hydroxychloroquine, Chloroquine or other 4-Aminoquinolines~* Pre-existing retinopathy or maculopathy~* Known Glucose-6-phosphate dehydrogenase deficiency (haemolytic anaemia, Favism)~* Haematopoietic systems diseases~* Myasthenia gravis~* Any other significant disease, disorder or finding which, in the opinion of the investigator, may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data~Additionally, clinical evaluation and laboratory values inform eligibility of the patient based on the judgement of the study team. These may include: total bilirubin, transaminase level, albumin concentration, haematological parameters, troponin and BNP levels, creatinine, creatinine kinase levels.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Hydroxychloroquine Sulfate (Type: EXPERIMENTAL): First dose: 800 mg. From 2nd day on, each patient will get 600 mg (3 capsules) once a day until day 7 (6 more does of 600 mg).
- Placebo (Type: PLACEBO_COMPARATOR): Equivalent number of placebo capsules at the day of inclusion (4 capsules) and the following days (3 capsules)

Based on this trial design, predict the completion outcome and termination type (if applicable).